EASL Video Podcasts

EASL Studio Podcast: JHEP Live – EASL CPGs on Hepatocellular Carcinoma: What’s New and How Will Practice Change?

Discover the latest updates from the updated EASL Clinical Practice Guidelines on Hepatocellular Carcinoma (HCC). This episode explores key advancements, their impact on clinical practice, and how they will shape the future of HCC diagnosis, treatment, and management. Join our faculty as they break down the changes and provide practical insights for healthcare professionals.
Moderator: Thomas BergFaculty: Peter Galle, Josep Llovet and Lorenza Rimassa
Related episodes
EASL Studio S6E4: World Cholangiocarcinoma Day: Highlighting Guidelines and Exploring the Horizon Beyond
EASL Studio S6E9: Therapy Hierarchy in HCC: A New Kid on the Block
EASL Studio S5E13: Basics in Decision-Making for Liver Cancer Treatment
EASL Studio Live from EASL Congress 2024: Advances in Systemic Treatments in Liver Cancer
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.

EASL Studio Podcast: 2025 Update on Steatotic Liver Disease: Rethinking Standard of Care

Join us for the season premiere of EASL Studio Season 8 as we unpack key insights from the Steatotic Liver Disease (SLD) Summit. Explore the evolving consensus on patient trajectories, advancements in ALD and MetALD treatment pathways, and the latest endpoint discussions. The episode also highlights a holistic approach to diagnosing and managing comorbidities and revisits the standard of care in light of breakthroughs in MASH treatments.
Moderator: Aleksander KragFaculty: Cyrielle Caussy, Sven Francque and Brian Lee
This EASL Studio is supported by Madrigal. EASL has received no input from Madrigal with regards to the content of this programme.
Related episodes
S7E3 – The changing face of Steatotic Liver Disease: Navigating new opportunities and emerging challenges
EASL Studio at the Congress 2024: SLD nomenclature: Need for refinement?
EASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscape
EASL Studio from EASL Congress 2023 – Steatotic liver disease global consensus to change nomenclature
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.

EASL DeepDive: Understanding and managing PBC symptoms

In this EASL DeepDive held on 03 July 2024, Palak Trivedi, Emma Culver, Andreas Kremer and Jessica Dyson explain the risk assessment in people with PBC as well as the mechanistic and treatment of fatigue and pruritus.
Learning objectives
Discover the latest mechanistic insights relating to the occurrence of PBC symptoms
Learn more about the holistic management of PBC symptoms, with a particular emphasis on fatigue and pruritus
Learn more about the current treatment options, their efficacy and limitations
Get a detailed understanding of the drugs in the pipeline for the near future
This EASL DeepDive webinar is supported by GSK and IPSEN. GSK and IPSEN have had no input into the content of this EASL DeepDive.

EASL DeepDive: Glucagon in MASH: A next step in “metabolic” drugs tackling liver disease?

In this EASL DeepDive held on 30 October 2024, Henning Grønbæk, Cyrielle Caussy, Mazen Noureddin and Frank Tacke provide an understanding of the role of glucagon and glucagon-receptors in physiology and in MASH patients. Additionally, they review key clinical trials and evaluate the integration of GLP-1 receptor agonists into current EASL-EASD-EASO clinical guidelines for practical patient management.
Learning objectives:
Understand the role of glucagon and glucagon-receptor in normal physiology and disease.
Understand the rationale of a combined dual GLP-1/GCG RA and its potential benefit compared to a GLP-1RA alone and thus gain insights into the mechanisms through which GLP-1 receptor agonists and GLP-1/GCG might affect liver pathology and metabolic regulation.
Discuss and review key clinical trials and ongoing development programs.
Evaluate how GLP-1RA can be integrated into current EASL-EASD-EASO CPGs, with a focus on practical applications and patient management strategies, giving potential guidance for future applications.
This EASL DeepDive webinar is supported by Boehringer Ingelheim. Boehringer Ingelheim has had no input into the content of this EASL DeepDive.

EASL DeepDive: Evolving insights in role and management of Alpha-1 Antitrypsin Deficiency

In this EASL DeepDive held on 06 November 2024, Alice Turner, Pavel Strnad, and Nicola Brunetti discuss and explore the changing insights in the management of Alpha-1 Antitrypsin Deficiency.
Learning objectives:
Learn more about the role of heterozygosity of alpha-1 as a risk factor for chronic liver disease, especially in the context of other causes such as MASLD or alcohol
Get a better understanding of the extrahepatic manifestations and the need for a multi-disciplinary approach
Learn more about screening: who to screen and how
Discover the general unmet needs related to AAT, with an emphasis on awareness and timely diagnosis
This EASL DeepDive webinar is supported by Takeda Pharmaceuticals. Takeda Pharmaceuticals has had no input into the content of this EASL DeepDive.

EASL DeepDive: What is the future of PBC treatment?

In this EASL DeepDive held on 25 February 2025,  Ana Lleo, Adriaan van der Meer, Gideon Hirschfield, and Bettina Hansen explore the future of primary biliary cholangitis (PBC) treatment. Discover the emerging therapies, current challenges and personalised approaches that are shaping the management of PBC.
Learning objectives
Learn more about the molecular mechanisms underlying the disease and the potential targets for drug therapy
Get a good understanding of the efficacy of the current drugs and the potential added value of the upcoming second line treatments for PBC and where to position these new treatments in the treatment landscape
Learn more about the evolving concepts regarding the endpoints in clinical trials for PBC
Get insights in the risk assessment of people living with PBC and criteria for second line therapy 
This EASL DeepDive webinar is supported by Gilead. Gilead has had no input into the content of this EASL DeepDive.